Risankizumab for the treatment of psoriasis

Area of Science:

• Immunodermatology
• Pharmacology

Background:

• The interleukin-23 (IL-23) and IL-17 pathway is integral to psoriasis pathogenesis.
• Targeting this pathway presents a significant therapeutic strategy for psoriasis management.

Purpose of the Study:

• To review risankizumab, a selective IL-23p19 inhibitor.
• To provide clinical references for risankizumab in psoriasis treatment.

Main Methods:

• Literature search on PubMed using keywords: 'risankizumab,' 'IL-23,' 'p19 subunit,' and 'psoriasis.'
• Inclusion of English language publications focusing on chemical properties, mechanism, pharmacokinetics, efficacy, and safety.

Main Results:

• Risankizumab is a humanized monoclonal antibody targeting the IL-23 p19 subunit.
• Clinical trials demonstrate risankizumab's superior efficacy over ustekinumab.
• The drug is generally well-tolerated, with upper respiratory tract infections as a common adverse event.

Conclusions:

• Risankizumab offers a valuable therapeutic option for psoriasis.
• Its selective inhibition of IL-23p19 provides a targeted approach to treatment.
• The drug's efficacy and safety profile support its role in clinical practice.